Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
![]() |
Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trialThe lancet oncology, 2019-03, Vol.20 (3), p.352-360 [Peer Reviewed Journal]2019 Elsevier Ltd ;Copyright © 2019 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Mar 2019 ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(18)30813-1 ;PMID: 30711522Full text available |
2 |
Material Type: Article
|
![]() |
Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trialThe lancet oncology, 2021-09, Vol.22 (9), p.1275-1289 [Peer Reviewed Journal]2021 Elsevier Ltd ;2021. Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(21)00342-9Full text available |
3 |
Material Type: Article
|
![]() |
The Incidence of Breast Cancer Recurrence 10-32 Years After Primary DiagnosisJNCI : Journal of the National Cancer Institute, 2022-03, Vol.114 (3), p.391-399 [Peer Reviewed Journal]The Author(s) 2021. Published by Oxford University Press. 2021 ;The Author(s) 2021. Published by Oxford University Press. ;ISSN: 0027-8874 ;EISSN: 1460-2105 ;DOI: 10.1093/jnci/djab202 ;PMID: 34747484Full text available |
4 |
Material Type: Article
|
![]() |
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trialThe lancet oncology, 2018-07, Vol.19 (7), p.904-915 [Peer Reviewed Journal]2018 Elsevier Ltd ;Copyright © 2018 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Jul 2018 ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(18)30292-4 ;PMID: 29804902Full text available |
5 |
Material Type: Article
|
![]() |
Triple-negative breast cancer molecular subtyping and treatment progressBreast cancer research : BCR, 2020-06, Vol.22 (1), p.1-61, Article 61 [Peer Reviewed Journal]COPYRIGHT 2020 BioMed Central Ltd. ;2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2020 ;ISSN: 1465-542X ;ISSN: 1465-5411 ;EISSN: 1465-542X ;DOI: 10.1186/s13058-020-01296-5 ;PMID: 32517735Full text available |
6 |
Material Type: Article
|
![]() |
HER2-positive breast cancerThe Lancet (British edition), 2017-06, Vol.389 (10087), p.2415-2429 [Peer Reviewed Journal]Elsevier Ltd ;2017 Elsevier Ltd ;Copyright © 2017 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Jun 17, 2017 ;2017. Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(16)32417-5 ;PMID: 27939064Full text available |
7 |
Material Type: Article
|
![]() |
Recurrence of breast cancer after regional or general anaesthesia: a randomised controlled trialThe Lancet (British edition), 2019-11, Vol.394 (10211), p.1807-1815 [Peer Reviewed Journal]2019 Elsevier Ltd ;2019. Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(19)32313-XFull text available |
8 |
Material Type: Article
|
![]() |
Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trialsThe lancet oncology, 2021-08, Vol.22 (8), p.1139-1150 [Peer Reviewed Journal]2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license ;Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. ;2021. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. This work is published under https://creativecommons.org/licenses/by/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license 2021 ;ISSN: 1470-2045 ;ISSN: 1474-5488 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(21)00288-6 ;PMID: 34339645Full text available |
9 |
Material Type: Article
|
![]() |
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast CancerThe New England journal of medicine, 2018-07, Vol.379 (2), p.111-121 [Peer Reviewed Journal]Copyright © 2018 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1804710 ;PMID: 29860917Full text available |
10 |
Material Type: Article
|
![]() |
Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b studyThe lancet oncology, 2018-07, Vol.19 (7), p.880-888 [Peer Reviewed Journal]2018 Elsevier Ltd ;Copyright © 2018 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Jul 2018 ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(18)30256-0 ;PMID: 29804905Full text available |
11 |
Material Type: Article
|
![]() |
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trialThe lancet oncology, 2018-01, Vol.19 (1), p.87-100 [Peer Reviewed Journal]2018 Elsevier Ltd ;Copyright © 2018 Elsevier Ltd. All rights reserved. ;COPYRIGHT 2018 Elsevier B.V. ;Copyright Elsevier Limited Jan 1, 2018 ;2018. Elsevier Ltd ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(17)30688-5 ;PMID: 29223745Full text available |
12 |
Material Type: Article
|
![]() |
Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patientsThe lancet oncology, 2018-03, Vol.19 (3), p.337-346 [Peer Reviewed Journal]2018 Elsevier Ltd ;Copyright © 2018 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Mar 1, 2018 ;2018. Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(18)30059-7 ;PMID: 29395867Full text available |
13 |
Material Type: Article
|
![]() |
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trialsThe Lancet (British edition), 2019-04, Vol.393 (10179), p.1440-1452 [Peer Reviewed Journal]2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license ;Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. ;2019. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. ;2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license 2019 ;ISSN: 0140-6736 ;ISSN: 1474-547X ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(18)33137-4 ;PMID: 30739743Full text available |
14 |
Material Type: Article
|
![]() |
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast CancerThe New England journal of medicine, 2016-11, Vol.375 (18), p.1738-1748 [Peer Reviewed Journal]Copyright © 2016 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1609709 ;PMID: 27717303Full text available |
15 |
Material Type: Article
|
![]() |
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast CancerThe New England journal of medicine, 2016-08, Vol.375 (8), p.717-729 [Peer Reviewed Journal]Copyright © 2016 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1602253 ;PMID: 27557300Full text available |
16 |
Material Type: Article
|
![]() |
Breast Cancer TreatmentAmerican family physician, 2021-08, Vol.104 (2), p.171-178 [Peer Reviewed Journal]Copyright American Academy of Family Physicians Aug 01, 2021 ;ISSN: 0002-838X ;EISSN: 1532-0650Full text available |
17 |
Material Type: Article
|
![]() |
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell CarcinomaThe New England journal of medicine, 2018-07, Vol.379 (4), p.341-351 [Peer Reviewed Journal]Copyright © 2018 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1805131 ;PMID: 29863979Full text available |
18 |
Material Type: Article
|
![]() |
Overall Survival with Ribociclib plus Endocrine Therapy in Breast CancerThe New England journal of medicine, 2019-07, Vol.381 (4), p.307-316 [Peer Reviewed Journal]Copyright © 2019 Massachusetts Medical Society. All rights reserved. ;Copyright © 2019 Massachusetts Medical Society. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1903765 ;PMID: 31166679Full text available |
19 |
Material Type: Article
|
![]() |
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trialThe lancet oncology, 2018-03, Vol.19 (3), p.295-309 [Peer Reviewed Journal]2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC-BY 4.0 license ;Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC-BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. ;Copyright Elsevier Limited Mar 1, 2018 ;2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC-BY 4.0 license 2018 ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(18)30079-2 ;PMID: 29449189Full text available |
20 |
Material Type: Article
|
![]() |
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trialThe lancet oncology, 2019-03, Vol.20 (3), p.339-351 [Peer Reviewed Journal]2019 Elsevier Ltd ;Copyright © 2019 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Mar 2019 ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(18)30862-3 ;PMID: 30795951Full text available |